TRANSFAC-Logo

TRANSFAC FACTOR TABLE, Release 2017.2 - public - 2017-06-30, (C) QIAGEN


AC T06138 XX ID T06138 XX DT 10.09.2004 (created); oke. DT 26.08.2014 (updated); yre. CO Copyright (C), QIAGEN. XX FA p73 XX SY p53-like transcription factor; p53-related protein; p73; tp73. XX OS human, Homo sapiens OC eukaryota; animalia; metazoa; chordata; vertebrata; tetrapoda; mammalia; eutheria; primates XX GE G005523 TP73; HGNC: tp73. XX CL C0057; P53; 6.3.1.0.3. XX SF generic entry for factors encoded by the human p73 gene; SF several alternative products are known, p73alpha T04931, p73beta T06137, p73gamma T06142, p73delta T06143, p73epsilon T06144, p73zeta T06145, p73kappa T06139, p73eta T06179, DeltaN p73alpha T06002, DeltaN p73beta T06003, DeltaNp73gamma T06013 [1] [3] [4] [6] [7] [18]; SF there is a number of aberrantly spliced transcripts (Delta exon2, Delta exon2/3, DeltaN-prime p73) regulated by the promoter TAp73 [17] [19]; SF DeltaN variants are generated from alternative transcription start site in exon3 and lack N-terminal transactivation domain [7]; SF variants alpha, beta, gamma refer to different C termini; SF high level homology between p53 and p73 [1]; SF forms stable homotetramers, is able to weakly associate with p63, but does not associate with p53 [5]; XX CP mRNA is upregulated upon differentiation of HL60 cell into monocytes, C2C12 (mouse) into muscle cells, P19 (mouse) into nerve cells [13]. XX FF TAp73variants act as tumor suppressors [1]; FF DeltaNp73 variants can act as oncogenes [19]; FF expression of DeltaNp73 variants is strongly up-regulated by p53 and TAp73 isoforms, thus forming a negative feedback loop [7] [11]; FF induces neuronal differentiation in neuroblastoma cell line via induction of pRB and N-Myc genes [8]; FF together with E2F-1 is a specific mediator of T-cell receptor activation induced cell death (TCR-AICD) [9]; FF mRNA expression, especially of isoforms p73alpha and p73beta, is activated by E2F-1 (high level), by E2F-2 and E2F-4 (intermediate level) [10] [12] [15]; XX IN T01077 Abl; human, Homo sapiens. IN T06131 p63; human, Homo sapiens. IN T22878 YAP-isoform3; human, Homo sapiens. IN T22876 YAP; human, Homo sapiens. XX MX M00761 V$P53DECAMER_Q2. MX M03558 V$P73_Q6. XX BS R33921. BS R34106. BS R34109. BS R63344. BS R57533. BS R57534. BS R57535. BS R33410. XX DR TRANSPATH: MO000028707. DR EMBL: AB031234; AB031234. DR EMBL: AF077616; DR EMBL: AF077617; DR EMBL: AF077618; DR EMBL: AF077619; DR EMBL: AF077620; DR EMBL: AF077621; DR EMBL: AF077624; DR EMBL: AF077625; DR EMBL: AF077626; DR EMBL: AF077627; DR EMBL: AF077628; DR EMBL: AF079082; DR EMBL: AF079083; DR EMBL: AF079084; DR EMBL: AF079085; DR EMBL: AF079086; DR EMBL: AF079087; DR EMBL: AF079088; DR EMBL: AF079089; DR EMBL: AF079090; DR EMBL: AF079091; DR EMBL: AF079092; DR EMBL: AF079093; DR EMBL: AF079094; DR EMBL: AL136528; DR EMBL: Y11416; DR UniProtKB: O15350; XX RN [1]; RE0017266. RX PUBMED: 9288759. RA Kaghad M., Bonnet H., Yang A., Creancier L., Biscan J. C., Valent A., Minty A., Chalon P., Lelias J. M., Dumont X., Ferrara P., McKeon F., Caput D. RT Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers RL Cell 90:809-819 (1997). RN [2]; RE0017268. RX PUBMED: 9721206. RA Mai M., Huang H., Reed C., Qian C., Smith J. S., Alderete B., Jenkins R., Smith D. I., Liu W. RT Genomic organization and mutation analysis of p73 in oligodendrogliomas with chromosome 1 p-arm deletions RL Genomics 51:359-363 (1998). RN [3]; RE0017269. RX PUBMED: 9802988. RA De Laurenzi V., Costanzo A., Barcaroli D., Terrinoni A., Falco M., Annicchiarico-Petruzzelli M., Levrero M., Melino G. RT Two new p73 splice variants, gamma and delta, with different transcriptional activity RL J. Exp. Med. 188:1763-1768 (1998). RN [4]; RE0017273. RX PUBMED: 10449409. RA Chi S. W., Ayed A., Arrowsmith C. H. RT Solution structure of a conserved C-terminal domain of p73 with structural homology to the SAM domain RL EMBO J. 18:4438-4445 (1999). RN [5]; RE0024342. RX PUBMED: 10373484. RA Davison T. S., Vagner C., Kaghad M., Ayed A., Caput D., Arrowsmith C. H. RT p73 and p63 are homotetramers capable of weak heterotypic interactions with each other but not with p53. RL J. Biol. Chem. 274:18709-18714 (1999). RN [6]; RE0024717. RX PUBMED: 10381648. RA De Laurenzi V. D., Catani M. V., Terrinoni A., Corazzari M., Melino G., Costanzo A., Levrero M., Knight R. A. RT Additional complexity in p73: induction by mitogens in lymphoid cells and identification of two new splicing variants epsilon and zeta. RL Cell Death Differ. 6:389-390 (1999). RN [7]; RE0024719. RX PUBMED: 11753569. RA Grob T. J., Novak U., Maisse C., Barcaroli D., Luthi A. U., Pirnia F., Hugli B., Graber H. U., De Laurenzi V., Fey M. F., Melino G., Tobler A. RT Human delta Np73 regulates a dominant negative feedback loop for TAp73 and p53. RL Cell Death Differ. 8:1213-1223 (2001). RN [8]; RE0024735. RX PUBMED: 10809758. RA De Laurenzi V., Raschella G., Barcaroli D., Annicchiarico-Petruzzelli M., Ranalli M., Catani M. V., Tanno B., Costanzo A., Levrero M., Melino G. RT Induction of neuronal differentiation by p73 in a neuroblastoma cell line. RL J. Biol. Chem. 275:15226-15231 (2000). RN [9]; RE0024737. RX PUBMED: 11034214. RA Lissy N. A., Davis P. K., Irwin M., Kaelin W. G., Dowdy S. F. RT A common E2F-1 and p73 pathway mediates cell death induced by TCR activation. RL Nature 407:642-645 (2000). RN [10]; RE0024738. RX PUBMED: 11034215. RA Irwin M., Marin M. C., Phillips A. C., Seelan R. S., Smith D. I., Liu W., Flores E. R., Tsai K. Y., Jacks T., Vousden K. H., Kaelin WG J. r. RT Role for the p53 homologue p73 in E2F-1-induced apoptosis. RL Nature 407:645-648 (2000). RN [11]; RE0024741. RX PUBMED: 11909952. RA Nakagawa T., Takahashi M., Ozaki T., Watanabe Ki K., Todo S., Mizuguchi H., Hayakawa T., Nakagawara A. RT Autoinhibitory regulation of p73 by Delta Np73 to modulate cell survival and death through a p73-specific target element within the Delta Np73 promoter. RL Mol. Cell. Biol. 22:2575-2585 (2002). RN [12]; RE0024742. RX PUBMED: 11988839. RA Seelan R. S., Irwin M., van der Stoop P., Qian C., Kaelin W.G., Liu W. RT The human p73 promoter: characterization and identification of functional E2F binding sites. RL Neoplasia 4:195-203 (2002). RN [13]; RE0024757. RX PUBMED: 11713281. RA Fontemaggi G., Gurtner A., Strano S., Higashi Y., Sacchi A., Piaggio G., Blandino G. RT The transcriptional repressor ZEB regulates p73 expression at the crossroad between proliferation and differentiation. RL Mol. Cell. Biol. 21:8461-8470 (2001). RN [14]; RE0024766. RX PUBMED: 10574463. RA Ding Y., Inoue T., Kamiyama J., Tamura Y., Ohtani-Fujita N., Igata E., Sakai T. RT Molecular cloning and functional characterization of the upstream promoter region of the human p73 gene. RL DNA Res. 6:347-351 (1999). RN [15]; RE0024767. RX PUBMED: 11101847. RA Stiewe T., Putzer B. M. RT Role of the p53-homologue p73 in E2F1-induced apoptosis. RL Nat. Genet. 26:464-469 (2000). RN [16]; RE0024769. RX PUBMED: 10490834. RA Ueda Y., Hijikata M., Takagi S., Chiba T., Shimotohno K. RT New p73 variants with altered C-terminal structures have varied transcriptional activities. RL Oncogene 18:4993-4998 (1999). RN [17]; RE0024778. RX PUBMED: 11844800. RA Stiewe T., Theseling C. C., Putzer B. M. RT Transactivation-deficient Delta TA-p73 inhibits p53 by direct competition for DNA binding: implications for tumorigenesis. RL J. Biol. Chem. 277:14177-14185 (2002). RN [18]; RE0024800. RX PUBMED: 11830511. RA Ishimoto O., Kawahara C., Enjo K., Obinata M., Nukiwa T., Ikawa S. RT Possible oncogenic potential of DeltaNp73: a newly identified isoform of human p73. RL Cancer Res. 62:636-641 (2002). RN [19]; RE0024805. RX PUBMED: 12097259. RA Stiewe T., Zimmermann S., Frilling A., Esche H., Putzer B. M. RT Transactivation-deficient DeltaTA-p73 acts as an oncogene. RL Cancer Res. 62:3598-3602 (2002). RN [20]; RE0036081. RX PUBMED: 12070014. RA Morena A., Riccioni S., Marchetti A., Polcini A. T., Mercurio A. M., Blandino G., Sacchi A., Falcioni R. RT Expression of the beta 4 integrin subunit induces monocytic differentiation of 32D/v-Abl cells. RL Blood 100:96-106 (2002). RN [21]; RE0049803. RX PUBMED: 16547931. RA Karpinich N. O., Tafani M., Schneider T., Russo M. A., Farber J. L. RT The course of etoposide-induced apoptosis in Jurkat cells lacking p53 and Bax. RL J. Cell. Physiol. 208:55-63 (2006). RN [22]; RE0050044. RX PUBMED: 16980297. RA Watson I. R., Blanch A., Lin D. C., Ohh M., Irwin M. S. RT Mdm2-mediated NEDD8 modification of TAp73 regulates its transactivation function. RL J. Biol. Chem. 281:34096-34103 (2006). RN [23]; RE0050052. RX PUBMED: 17452332. RA Furuya K., Ozaki T., Hanamoto T., Hosoda M., Hayashi S., Barker P. A., Takano K., Matsumoto M., Nakagawara A. RT Stabilization of p73 by nuclear IKK-alpha mediates cisplatin-induced apoptosis. RL J. Biol. Chem. 282:18365-18378 (2007). RN [24]; RE0050157. RX PUBMED: 17535448. RA Paliwal P., Radha V., Swarup G. RT Regulation of p73 by Hck through kinase-dependent and independent mechanisms. RL BMC Mol. Biol. 8:45 (2007). RN [25]; RE0024368. RX PUBMED: 15070730. RA Aqeilan R. I., Pekarsky Y., Herrero J. J., Palamarchuk A., Letofsky J., Druck T., Trapasso F., Han S. Y., Melino G., Huebner K., Croce C. M. RT Functional association between Wwox tumor suppressor protein and p73, a p53 homolog. RL Proc. Natl. Acad. Sci. USA 101:4401-4406 (2004). RN [26]; RE0024372. RX PUBMED: 15175157. RA Mantovani F., Piazza S., Gostissa M., Strano S., Zacchi P., Mantovani R., Blandino G., Del Sal G. RT Pin1 Links the Activities of c-Abl and p300 in Regulating p73 Function. RL Mol. Cell 14:625-636 (2004). XX //